Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents – Yahoo Finance
|
Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR–T cells patents
Yahoo Finance The agreement includes Celyad's intellectual property rights under United States Patent No. 9,181,527 related to allogeneic human primary T–Cells that are engineered to be T–Cell Receptor (TCR) deficient and express a Chimeric Antigen Receptor (CAR). |
